What is Precision Neuroscience Corporation?
Precision Neuroscience Corporation is a mission-driven enterprise dedicated to the development and commercialization of advanced brain-computer interfaces. By prioritizing minimally invasive surgical techniques, the company aims to provide therapeutic solutions for previously intractable medical conditions, including refractory epilepsy, blindness, paralysis, and cognitive impairment. With a decade-long commitment to building a comprehensive intellectual property portfolio, the firm is uniquely positioned to bridge the gap between neuroscientific research and clinical application. Their strategic focus on high-impact medical needs has attracted significant backing from global venture capital firms and specialized life science investors, facilitating the transition from experimental development to large-scale clinical validation.
How much funding has Precision Neuroscience Corporation raised?
Precision Neuroscience Corporation has raised a total of $155M across 3 funding rounds:
Series A
$12M
Series B
$41M
Series C
$102M
Series A (2021): $12M with participation from Steadview Capital and B Capital Group
Series B (2023): $41M led by Alumni Ventures, Forepont Capital Partners, Draper Associates, and Mubadala GE Capital PJSC
Series C (2024): $102M supported by General Equity Holdings and B Capital Group
Key Investors in Precision Neuroscience Corporation
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
Forepont Capital Partners
Forepont Capital Partners is a global asset manager specializing in healthcare and life sciences, providing scientific and operational support to biotech and medtech start-ups.
Draper Associates
Draper Associates is a global venture capital firm with over 40 years of experience in funding transformative companies across sectors including biotech and AI.
What's next for Precision Neuroscience Corporation?
With the successful closure of this latest financing round, Precision Neuroscience is poised to accelerate its clinical trial roadmap and expand its operational footprint. The capital will likely be deployed to enhance the scalability of its BCI hardware and software, ensuring that the technology meets the rigorous standards required for widespread medical adoption. As the company moves into this next phase of growth, the focus will shift toward securing regulatory milestones and deepening partnerships within the healthcare ecosystem. The strategic involvement of top-tier investors suggests a clear path toward commercialization, with the potential to redefine the standard of care for patients suffering from severe neurological disorders.
See full Precision Neuroscience Corporation company page
